Coelho Rogerio Vivaldi

Coelho Rogerio Vivaldi, listed as chief executive, has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Spark Therapeutics, Inc., Crinetics Pharmaceuticals, Inc. and Sigilon Therapeutics, Inc. Over a trading history stretching from 20 April 2016 to 1 September 2026, the count stands at 29 filings.

In open-market terms, that means 1 purchase worth €102k on one side and 6 sales worth €827k on the other. Taken together, the sales exceed the purchases by €725k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 6 share grants and 11 option exercises. Since January 2026: no purchases and 2 sales on the market.

Most recently, on 1 September 2026, the filings show a transaction worth €973k in Crinetics Pharmaceuticals, Inc. The last purchase on record was published on 9 June 2023, which is 1,230 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.